CareDx, Inc. (NASDAQ:CDNA – Get Free Report) CEO John Walter Hanna, Jr. sold 4,835 shares of the company’s stock in a transaction dated Thursday, June 4th. The shares were sold at an average price of $24.00, for a total transaction of $116,040.00. Following the completion of the transaction, the chief executive officer owned 671,640 shares in the company, valued at $16,119,360. This trade represents a 0.71% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
CareDx Trading Down 1.3%
NASDAQ CDNA traded down $0.30 during trading on Monday, reaching $21.95. The company’s stock had a trading volume of 366,082 shares, compared to its average volume of 713,517. The firm has a market capitalization of $1.13 billion, a price-to-earnings ratio of -137.19 and a beta of 2.49. CareDx, Inc. has a 12 month low of $10.96 and a 12 month high of $24.02. The firm has a 50 day moving average price of $20.23 and a 200 day moving average price of $19.39.
CareDx (NASDAQ:CDNA – Get Free Report) last announced its quarterly earnings data on Tuesday, April 28th. The company reported $0.34 earnings per share for the quarter, beating the consensus estimate of $0.11 by $0.23. The firm had revenue of $117.70 million during the quarter, compared to analysts’ expectations of $102.03 million. CareDx had a negative return on equity of 2.65% and a negative net margin of 2.01%.The company’s quarterly revenue was up 39.3% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.09 EPS. On average, equities analysts forecast that CareDx, Inc. will post 0.22 EPS for the current fiscal year.
Analysts Set New Price Targets
View Our Latest Research Report on CDNA
Institutional Investors Weigh In On CareDx
Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Bamco Inc. NY grew its holdings in shares of CareDx by 29.5% during the 3rd quarter. Bamco Inc. NY now owns 3,155,180 shares of the company’s stock valued at $45,876,000 after purchasing an additional 719,523 shares during the last quarter. State Street Corp raised its position in CareDx by 6.7% in the fourth quarter. State Street Corp now owns 2,737,752 shares of the company’s stock valued at $51,579,000 after purchasing an additional 171,303 shares during the last quarter. Deerfield Management Company L.P. bought a new position in CareDx in the third quarter valued at about $31,857,000. Braidwell LP bought a new position in CareDx in the third quarter valued at about $31,738,000. Finally, ARK Investment Management LLC raised its position in CareDx by 3.4% in the third quarter. ARK Investment Management LLC now owns 2,170,625 shares of the company’s stock valued at $31,561,000 after purchasing an additional 70,468 shares during the last quarter.
CareDx Company Profile
CareDx, Inc (NASDAQ: CDNA) is a precision diagnostics company focused on the care of transplant patients. The firm develops and commercializes non‐invasive tests designed to detect organ transplant rejection and infection risk, helping physicians make informed management decisions throughout the post‐transplant journey.
The company’s core product portfolio includes AlloMap®, a gene expression profiling test for heart transplant recipients, and AlloSure®, a donor‐derived cell‐free DNA assay used primarily in kidney transplant monitoring.
Featured Stories
- Five stocks we like better than CareDx
- 3 Stocks With Fresh Catalysts to Watch Before the July 4
- Amprius Insiders Are Selling: Should Investors Be Worried?
- A Weaker Dollar Could Put These 3 Industrial Stocks Back in Focus
- A Market Rotation Toward Quality Will Benefit These 3 ETFs
Receive News & Ratings for CareDx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CareDx and related companies with MarketBeat.com's FREE daily email newsletter.
